NCT00257621View on ClinicalTrials.gov

GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions
Infection, Human Immunodeficiency Virus IHIV Infection
Interventions
DRUG

GW640385

DRUG

Ritonavir

Trial Locations (9)

20009

GSK Investigational Site, Washington D.C.

23666

GSK Investigational Site, Hampton

30308

GSK Investigational Site, Atlanta

32804

GSK Investigational Site, Orlando

33308

GSK Investigational Site, Fort Lauderdale

85006

GSK Investigational Site, Phoenix

87505

GSK Investigational Site, Santa Fe

94115

GSK Investigational Site, San Francisco

98104

GSK Investigational Site, Seattle

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY

NCT00257621 - GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults | Biotech Hunter | Biotech Hunter